A self-adjuvanted VLPs-based Covid-19 vaccine proven versatile, safe, and highly protective.
Vaccines, Virus-Like Particle
/ immunology
COVID-19 Vaccines
/ immunology
Animals
COVID-19
/ prevention & control
SARS-CoV-2
/ immunology
Mice
Humans
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
Spike Glycoprotein, Coronavirus
/ immunology
Female
Adjuvants, Immunologic
/ administration & dosage
Adjuvants, Vaccine
Vaccination
/ methods
Mice, Inbred BALB C
COVID-19
SARS-CoV-2
VLPs platform
Vaccine
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
16 10 2024
16 10 2024
Historique:
received:
19
06
2024
accepted:
10
10
2024
medline:
17
10
2024
pubmed:
17
10
2024
entrez:
16
10
2024
Statut:
epublish
Résumé
Vaccination has played a critical role in mitigating COVID-19. Despite the availability of licensed vaccines, there remains a pressing need for improved vaccine platforms that provide high protection, safety, and versatility, while also reducing vaccine costs. In response to these challenges, our aim is to create a self-adjuvanted vaccine against SARS-CoV-2, utilizing Virus-Like Particles (VLPs) as the foundation. To achieve this, we produced bacteriophage (Qβ) VLPs in a prokaryotic system and purified them using a rapid and cost-effective strategy involving organic solvents. This method aims to solubilize lipids and components of the cell membrane to eliminate endotoxins present in bacterial samples. For vaccine formulation, Receptor Binding Domain (RBD) antigens were conjugated using chemical crosslinkers, a process compatible with Good Manufacturing Practice (GMP) standards. Transmission Electron Microscopy (TEM) confirmed the expected folding and spatial configuration of the QβVLPs vaccine. Additionally, vaccine formulation assessment involved SDS-PAGE stained with Coomassie Brilliant Blue, Western blotting, and stereomicroscopic experiments. In vitro and in vivo evaluations of the vaccine formulation were conducted to assess its capacity to induce a protective immune response without causing side effects. Vaccine doses of 20 µg and 50 µg stimulated the production of neutralizing antibodies. In in vivo testing, the group of animals vaccinated with 50 µg of vaccine formulation provided complete protection against virus infection, maintaining stable body weight without showing signs of disease. In conclusion, the QβVLPs-RBD vaccine has proven to be effective and safe, eliminating the necessity for supplementary adjuvants and offering a financially feasible approach. Moreover, this vaccine platform demonstrates flexibility in targeting Variants of Concern (VOCs) via established conjugation protocols with VLPs.
Identifiants
pubmed: 39414952
doi: 10.1038/s41598-024-76163-w
pii: 10.1038/s41598-024-76163-w
doi:
Substances chimiques
Vaccines, Virus-Like Particle
0
COVID-19 Vaccines
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
Adjuvants, Immunologic
0
Adjuvants, Vaccine
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
24228Subventions
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo
ID : 2020/09404-0 (Post-doc Scholarship)
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo
ID : AL: 2021/03102-5 (PhD Scholarship
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo
ID : NC 2021/03508-1
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo
ID : WAPS 2021/08468-8 (PhD Scholarship)
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo
ID : GC-M: 2019/14526-0, 2020/04667-3
Informations de copyright
© 2024. The Author(s).
Références
Kumar, A. et al. SARS-CoV-2-specific virulence factors in COVID-19. J. Med. Virol. 93 (3), 1343–1350. https://doi.org/10.1002/jmv.26615 (2021). Epub 2020 Nov 1. PMID: 33085084.
doi: 10.1002/jmv.26615
pubmed: 33085084
World Health Organization. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/
DeGrace, M. M. et al. Defining the risk of SARS-CoV-2 variants on immune protection. Nature. 605, 640–652 (2022).
doi: 10.1038/s41586-022-04690-5
pubmed: 35361968
pmcid: 9345323
Prates-Syed, W. A. et al. VLP-Based COVID-19 vaccines: an adaptable technology against the threat of New variants. Vaccines (Basel). 9 (12), 1409. https://doi.org/10.3390/vaccines9121409 (2021). PMID: 34960155; PMCID: PMC8708688.
doi: 10.3390/vaccines9121409
pubmed: 34960155
Chirico, F., da Silva, J. A. T., Tsigaris, P. & Sharun, K. Safety & effectiveness of COVID-19 vaccines: a narrative review. Indian J. Med. Res. 155, 91–104 (2022).
doi: 10.4103/ijmr.IJMR_474_21
pubmed: 35859436
pmcid: 9552389
Jackson, C. B., Farzan, M., Chen, B. & Choe, H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell. Biol. 23, 3–20 (2022).
doi: 10.1038/s41580-021-00418-x
pubmed: 34611326
Min, L. & Sun, Q. Antibodies and vaccines target RBD of SARS-CoV-2. Front. Mol. Biosci. 8, 671633 (2021).
doi: 10.3389/fmolb.2021.671633
pubmed: 33968996
pmcid: 8100443
Premkumar, L. et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci. Immunol. 5 (48), eabc8413. https://doi.org/10.1126/sciimmunol.abc8413 (2020). PMID: 32527802; PMCID: PMC7292505.
doi: 10.1126/sciimmunol.abc8413
pubmed: 32527802
pmcid: 7292505
Pollet, J., Chen, W. H. & Strych, U. Recombinant protein vaccines, a proven approach against coronavirus pandemics. Adv. Drug Deliv Rev. 170, 71–82. https://doi.org/10.1016/j.addr.2021.01.001 (2021). Epub 2021 Jan 7. PMID: 33421475; PMCID: PMC7788321.
doi: 10.1016/j.addr.2021.01.001
pubmed: 33421475
pmcid: 7788321
Pulendran, B. S., Arunachalam, P. & O’Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454–475 (2021).
doi: 10.1038/s41573-021-00163-y
pubmed: 33824489
pmcid: 8023785
Schijns, V. et al. Modulation of immune responses using adjuvants to facilitate therapeutic vaccination. Immunol. Rev. 296 (1), 169–190. https://doi.org/10.1111/imr.12889 (2020). Epub 2020 Jun 28. PMID: 32594569; PMCID: PMC7497245.
doi: 10.1111/imr.12889
pubmed: 32594569
pmcid: 7497245
Zhang, Y. N., Auclair, S. & Zhu, J. Virus-like nanoparticle vaccines for inducing long-lasting immunity against infectious diseases. Natl. Sci. Rev. 11 (4), nwae032. https://doi.org/10.1093/nsr/nwae032 (2024). PMID: 38440215; PMCID: PMC10911813.
doi: 10.1093/nsr/nwae032
pubmed: 38440215
pmcid: 10911813
Gao, X. et al. Nanovaccines for advancing long-lasting immunity against Infectious diseases. ACS Nano. 17 (24), 24514–24538. https://doi.org/10.1021/acsnano.3c07741 (2023). Epub 2023 Dec 6. PMID: 38055649.
doi: 10.1021/acsnano.3c07741
pubmed: 38055649
Kang, S. M. et al. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One. 4 (3), e4667. https://doi.org/10.1371/journal.pone.0004667 (2009). Epub 2009 Mar 2. PMID: 19252744; PMCID: PMC2646145.).
doi: 10.1371/journal.pone.0004667
pubmed: 19252744
pmcid: 2646145
Mohsen, M. O. L., Zha, Cabral-Miranda, G. & Bachmann, M. F. Major findings and recent advances in virus-like particle (VLP)-based vaccines. Semin Immunol. 34, 123–132 (2017).
doi: 10.1016/j.smim.2017.08.014
pubmed: 28887001
Gupta, R. et al. Platforms, advances, and technical challenges in virus-like particles-based vaccines. Front. Immunol. 14, 1123805. https://doi.org/10.3389/fimmu.2023.1123805 (2023). PMID: 36845125; PMCID: PMC9947793.
doi: 10.3389/fimmu.2023.1123805
pubmed: 36845125
pmcid: 9947793
Tariq, H., Batool, S., Asif, S., Ali, M. & Abbasi, B. H. Virus-like particles: Revolutionary platforms for developing vaccines against emerging Infectious diseases. Front. Microbiol. 12, 790121. https://doi.org/10.3389/fmicb.2021.790121 (2022). PMID: 35046918; PMCID: PMC8761975.
doi: 10.3389/fmicb.2021.790121
pubmed: 35046918
pmcid: 8761975
Dhawan, M., Saied, A. R. A. & Sharma, M. Virus-like particles (VLPs)-based vaccines against COVID-19: where do we stand amid the ongoing evolution of SARS-CoV-2? Health Sci. Rev. 9, 100127. https://doi.org/10.1016/j.hsr.2023.100127 (2023).
doi: 10.1016/j.hsr.2023.100127
Mohsen, M. O. et al. Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination. J. Controlled Release 2017 March 251: 92–100. https://doi.org/10.1016/j.jconrel.2017.02.031
Qian, C. et al. Recent progress on the versatility of Virus-Like particles. Vaccines (Basel). 8 (1), 139. https://doi.org/10.3390/vaccines8010139 (2020). PMID: 32244935; PMCID: PMC7157238.
doi: 10.3390/vaccines8010139
pubmed: 32244935
Zhou, F. & Zhang, D. Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates. Front. Immunol. 14, 1238649. https://doi.org/10.3389/fimmu.2023.1238649 (2023). PMID: 38022657; PMCID: PMC10652786.
doi: 10.3389/fimmu.2023.1238649
pubmed: 38022657
pmcid: 10652786
Hadj Hassine, I., Ben, M., Almalki, M. & Gharbi, M. A. Virus-like particles as powerful vaccination strategy against human viruses. Rev. Med. Virol. 34 (1), e2498. https://doi.org/10.1002/rmv.2498 (2024). Epub 2023 Dec 20. PMID: 38116958.
doi: 10.1002/rmv.2498
pubmed: 38116958
Mazalovska, M. & Kouokam, J. C. Progress in the production of Virus-Like particles for vaccination against Hepatitis E Virus. Viruses. 12 (8), 826. https://doi.org/10.3390/v12080826 (2020). PMID: 32751441; PMCID: PMC7472025.
doi: 10.3390/v12080826
pubmed: 32751441
pmcid: 7472025
Wang, D. et al. Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles. Nat. Commun. 11 (1), 2841. https://doi.org/10.1038/s41467-020-16639-1 (2020). PMID: 32503989; PMCID: PMC7275066.
doi: 10.1038/s41467-020-16639-1
pubmed: 32503989
pmcid: 7275066
Bahar, M. W. et al. Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines. NPJ Vaccines. 6 (1), 5. https://doi.org/10.1038/s41541-020-00267-3 (2021). PMID: 33420068; PMCID: PMC7794334.
doi: 10.1038/s41541-020-00267-3
pubmed: 33420068
pmcid: 7794334
Cabral-Miranda, G. et al. M. DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines. Diseases ;6(4):107. doi: https://doi.org/10.3390/diseases6040107 . (2018). PMID: 30469323; PMCID: PMC6313579.
Cabral-Miranda, G. et al. Microcrystalline Tyrosine (MCT
doi: 10.3390/vaccines5040032
pubmed: 28953265
Cabral-Miranda, G. et al. Virus-like particle (VLP) plus Microcrystalline Tyrosine (MCT) adjuvants enhance vaccine efficacy improving T and B cell immunogenicity and protection against Plasmodium berghei/vivax. Vaccines (Basel). 5 (2), 10. https://doi.org/10.3390/vaccines5020010 (2017). PMID: 28468322; PMCID: PMC5492007.
doi: 10.3390/vaccines5020010
pubmed: 28468322
Roesti, E. S. et al. Vaccination against Amyloidogenic Aggregates in pancreatic islets prevents development of type 2 diabetes Mellitus. Vaccines (Basel). 8 (1), 116. https://doi.org/10.3390/vaccines8010116 (2020). PMID: 32131431; PMCID: PMC7157615.
doi: 10.3390/vaccines8010116
pubmed: 32131431
pmcid: 7157615
Doucet, M. et al. Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles. PLoS One. 12 (8), e0181844. https://doi.org/10.1371/journal.pone.0181844 (2017). PMID: 28797124; PMCID: PMC5552317.
doi: 10.1371/journal.pone.0181844
pubmed: 28797124
pmcid: 5552317
Vanderheiden, A. et al. Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 neutralizing antibodies. Curr. Protoc. Immunol. 131 (1), e116. https://doi.org/10.1002/cpim.116 (2020). PMID: 33215858; PMCID: PMC7864545.
doi: 10.1002/cpim.116
pubmed: 33215858
pmcid: 7864545
Martino, M. L., Crooke, S. N., Manchester, M. & Finn, M. G. Single-point mutations in Qβ Virus-like particles change binding to cells. Biomacromolecules. 22 (8), 3332–3341. https://doi.org/10.1021/acs.biomac.1c00443 (2021). Epub 2021 Jul 12. PMID: 34251176; PMCID: PMC9068229.
doi: 10.1021/acs.biomac.1c00443
pubmed: 34251176
pmcid: 9068229
Sungsuwan, S. et al. Structure guided design of bacteriophage Qβ mutants as Next Generation Carriers for Conjugate vaccines. ACS Chem. Biol. 17 (11), 3047–3058. https://doi.org/10.1021/acschembio.1c00906 (2022). Epub 2022 Feb 10. PMID: 35142488; PMCID: PMC9363528.
doi: 10.1021/acschembio.1c00906
pubmed: 35142488
pmcid: 9363528
Brito, L. A. & Singh, M. Acceptable levels of endotoxin in vaccine formulations during preclinical research. J Pharm Sci. ;100(1):34 – 7. doi: (2011). https://doi.org/10.1002/jps.22267 . PMID: 20575063.
Hou, X. et al. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078–1094. https://doi.org/10.1038/s41578-021-00358-0 (2021).
doi: 10.1038/s41578-021-00358-0
pmcid: 8353930
Huang, X. et al. The landscape of mRNA nanomedicine. Nat. Med. 28, 2273–2287. https://doi.org/10.1038/s41591-022-02061-1 (2022).
doi: 10.1038/s41591-022-02061-1
pubmed: 36357682
Schoenmaker, L. et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int. J. Pharm. 601, 120586. https://doi.org/10.1016/j.ijpharm.2021.120586 (2021). Epub 2021 Apr 9. PMID: 33839230; PMCID: PMC8032477.
doi: 10.1016/j.ijpharm.2021.120586
pmcid: 8032477
Li, X. et al. Nanoparticle technology for mRNA: delivery strategy, clinical application and developmental landscape. Theranostics. 14 (2), 738–760. https://doi.org/10.7150/thno.84291 (2024). PMID: 38169577; PMCID: PMC10758055.
doi: 10.7150/thno.84291
pubmed: 38169577
pmcid: 10758055
Kon, E., Elia, U. & Peer, D. Principles for designing an optimal mRNA lipid nanoparticle vaccine. Curr. Opin. Biotechnol. 73, 329–336. https://doi.org/10.1016/j.copbio.2021.09.016 (2022). Epub 2021 Oct 26. PMID: 34715546; PMCID: PMC8547895.
doi: 10.1016/j.copbio.2021.09.016
pubmed: 34715546
Wang, S. et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal. Transduct. Target. Ther. 8 (1), 149. https://doi.org/10.1038/s41392-023-01408-5 (2023). PMID: 37029123; PMCID: PMC10081433.
doi: 10.1038/s41392-023-01408-5
pubmed: 37029123
pmcid: 10081433
Shirley, J. L., de Jong, Y. P., Terhorst, C. & Herzog, R. W. Immune responses to viral gene therapy vectors. Mol. Ther. 28 (3), 709–722. https://doi.org/10.1016/j.ymthe.2020.01.001 (2020). Epub 2020 Jan 10. PMID: 31968213; PMCID: PMC7054714.
doi: 10.1016/j.ymthe.2020.01.001
pubmed: 31968213
pmcid: 7054714
Chan, Y. K. et al. Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses. Sci. Transl Med. 13 (580), eabd3438. https://doi.org/10.1126/scitranslmed.abd3438 (2021). PMID: 33568518; PMCID: PMC8409505.
doi: 10.1126/scitranslmed.abd3438
pubmed: 33568518
pmcid: 8409505
Syed, A. M. et al. Rapid assessment of SARS-CoV-2-evolved variants using virus-like particles. Science. 374 (6575), 1626–1632. https://doi.org/10.1126/science.abl6184 (2021). Epub 2021 Nov 4. PMID: 34735219; PMCID: PMC9005165.
doi: 10.1126/science.abl6184
pubmed: 34735219
pmcid: 9005165
Johnson, B. A. & Menachery, V. D. A new tool to probe SARS-CoV-2 variants. Science. 374 (6575), 1557–1558. https://doi.org/10.1126/science.abn3781 (2021). Epub 2021 Dec 23. PMID: 34941409.
doi: 10.1126/science.abn3781
pubmed: 34941409
Vuitika, L. et al. Vaccines against emerging and neglected infectious diseases: an overview. Vaccines (Basel). 10 (9), 1385. https://doi.org/10.3390/vaccines10091385 (2022). PMID: 36146463; PMCID: PMC9503027.
doi: 10.3390/vaccines10091385
pubmed: 36146463
Kaul, V. et al. Lessons learned from a global perspective of Coronavirus Disease-2019. Clin. Chest Med. 44 (2), 435–449 (2023). Epub 2022 Nov 24. PMID: 37085231; PMCID: PMC9684102.
doi: 10.1016/j.ccm.2022.11.020
pubmed: 37085231
Brown, S. D., Fiedler, J. D. & Finn, M. G. Assembly of hybrid bacteriophage Qbeta virus-like particles. Biochemistry. 48 (47), 11155–11157. https://doi.org/10.1021/bi901306 (2009). PMID: 19848414; PMCID: PMC2799296.
doi: 10.1021/bi901306
pubmed: 19848414
Chang, J. Y., Gorzelnik, K. V., Thongchol, J. & Zhang, J. Structural Assembly of Qβ Virion and its diverse forms of virus-like particles. Viruses. 14 (2), 225. https://doi.org/10.3390/v14020225 (2022). PMID: 35215818; PMCID: PMC8880383.
doi: 10.3390/v14020225
pubmed: 35215818
pmcid: 8880383
Frietze, K. M., Peabody, D. S. & Chackerian, B. Engineering virus-like particles as vaccine platforms. Curr. Opin. Virol. 18, 44–49. https://doi.org/10.1016/j.coviro.2016.03.001 (2016). Epub 2016 Mar 29. PMID: 27039982; PMCID: PMC4983494.
doi: 10.1016/j.coviro.2016.03.001
pubmed: 27039982
pmcid: 4983494
Liao, W. et al. Characterization of T-Dependent and T-Independent B cell responses to a virus-like particle. J. Immunol. 198 (10), 3846–3856. https://doi.org/10.4049/jimmunol.1601852 (2017). Epub 2017 Apr 17. PMID: 28416599.
doi: 10.4049/jimmunol.1601852
pubmed: 28416599
Ambühl, P. M. et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens. ;25(1):63–72. doi: (2007). https://doi.org/10.1097/HJH.0b013e32800ff5d6 . PMID: 17143175.
Maurer, P. et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol. ;35(7):2031-40. doi: (2005). https://doi.org/10.1002/eji.200526285 . PMID: 15971275.
Nooraei, S. et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J. Nanobiotechnol. 19 (1), 59. https://doi.org/10.1186/s12951-021-00806-7 (2021). PMID: 33632278; PMCID: PMC7905985.
doi: 10.1186/s12951-021-00806-7
Huang, X., Wang, X., Zhang, J., Xia, N. & Zhao, Q. Escherichia coli-derived virus-like particles in vaccine development. NPJ Vaccines. 2, 3. https://doi.org/10.1038/s41541-017-0006-8 (2017). PMID: 29263864; PMCID: PMC5627247.
doi: 10.1038/s41541-017-0006-8
pubmed: 29263864
pmcid: 5627247
Markov, P. V. et al. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 21, 361–379 (2023).
doi: 10.1038/s41579-023-00878-2
pubmed: 37020110
Nabel, K. G. et al. Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. Science. 375 (6578), eabl6251. https://doi.org/10.1126/science.abl6251 (2022). Epub 2022 Jan 21. PMID: 34855508; PMCID: PMC9127715.
doi: 10.1126/science.abl6251
pubmed: 34855508
Smit, M. J. et al. First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2. Lancet Microbe. 4 (3), e140–e148 (2023).
doi: 10.1016/S2666-5247(22)00337-8
pubmed: 36681093
pmcid: 9848408
Fougeroux, C. et al. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity. Nat. Commun. 12 (1), 324 (2021).
doi: 10.1038/s41467-020-20251-8
pubmed: 33436573
pmcid: 7804149
Limonta-Fernández, M. et al. An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen. N Biotechnol. 72, 11–21 (2022). Epub 2022 Aug 8. PMID: 35953030; PMCID: PMC9359770.
doi: 10.1016/j.nbt.2022.08.002
pubmed: 35953030
pmcid: 9359770
Hernández-Bernal, F. et al. Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: a randomised, double-blind, placebo-controlled, phase 1–2 clinical trial (ABDALA Study). EClinicalMedicine. 46, 101383. https://doi.org/10.1016/j.eclinm.2022.101383 (2022). Epub 2022 Apr 9. PMID: 35434578; PMCID: PMC8994669.
doi: 10.1016/j.eclinm.2022.101383
pubmed: 35434578
pmcid: 8994669
Yang, S. et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect. Dis. 21 (8), 1107–1119. https://doi.org/10.1016/S1473-3099(21)00127-4 (2021). Epub 2021 Mar 24. PMID: 33773111; PMCID: PMC7990482.
doi: 10.1016/S1473-3099(21)00127-4
pubmed: 33773111
pmcid: 7990482
Dai, L. et al. ZF2001 Global Trial Group. Efficacy and Safety of the RBD-Dimer-Based COVID-19 Vaccine ZF2001 in Adults. N Engl J Med. ;386(22):2097–2111. doi: 10.1056/NEJMoa2202261. Epub 2022 May 4. PMID: 35507481; PMCID: PMC9127771. (2022).
Valdes-Balbin, Y. et al. Verez Bencomo V. SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine induces a strong neutralizing immunity in Preclinical studies. ACS Chem. Biol. 16 (7), 1223–1233. https://doi.org/10.1021/acschembio.1c00272 (2021). Epub 2021 Jul 4. PMID: 34219448.
doi: 10.1021/acschembio.1c00272
pubmed: 34219448
Chen, W. H. et al. Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate. Biochim. Biophys. Acta Gen. Subj. 1865 (6), 129893. https://doi.org/10.1016/j.bbagen.2021.129893 (2021). Epub 2021 Mar 14. PMID: 33731300; PMCID: PMC7955913.
doi: 10.1016/j.bbagen.2021.129893
pubmed: 33731300
pmcid: 7955913
Thuluva, S. et al. Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials. EBioMedicine. 83, 104217 (2022). Epub 2022 Aug 12. PMID: 35970020; PMCID: PMC9372721.
doi: 10.1016/j.ebiom.2022.104217
pubmed: 35970020
pmcid: 9372721
Mahboob, T. et al. Development of SARS-CoV-2 vaccine: challenges and prospects. Diseases. 11 (2), 64. https://doi.org/10.3390/diseases11020064 (2023). PMID: 37092446; PMCID: PMC10123684.
doi: 10.3390/diseases11020064
pubmed: 37092446
pmcid: 10123684
Zepeda-Cervantes, J., Ramírez-Jarquín, J. O. & Vaca, L. Interaction between Virus-Like particles (VLPs) and Pattern Recognition Receptors (PRRs) from dendritic cells (DCs): toward Better Engineering of VLPs. Front. Immunol. 11, 1100. https://doi.org/10.3389/fimmu.2020.01100 (2020). PMID: 32582186; PMCID: PMC7297083.
doi: 10.3389/fimmu.2020.01100
pubmed: 32582186
pmcid: 7297083
Collins, A. M. IgG subclass co-expression brings harmony to the quartet model of murine IgG function. Immunol. Cell. Biol. 94 (10), 949–954. https://doi.org/10.1038/icb.2016.65 (2016). Epub 2016 Aug 9. PMID: 27502143.
doi: 10.1038/icb.2016.65
pubmed: 27502143
Gomes, C., Roesti, A., El-Turabi, E. S. & Bachmann, A. Type of RNA packed in VLPs impacts IgG class switching-implications for an Influenza Vaccine Design. Vaccines (Basel). 7 (2), 47. https://doi.org/10.3390/vaccines7020047 (2019). PMID: 31167472; PMCID: PMC6630894.
doi: 10.3390/vaccines7020047
Kaplan, C. et al. Th1 and Th2 cytokines regulate proteoglycan-specific autoantibody isotypes and arthritis. Arthritis Res. 4 (1), 54–58. https://doi.org/10.1186/ar383 (2002). Epub 2001 Oct 2. PMID: 11879537; PMCID: PMC64852.
doi: 10.1186/ar383
pubmed: 11879537
Firacative, C. et al. Identification of T helper (th)1- and Th2-associated antigens of Cryptococcus neoformans in a murine model of pulmonary infection. Sci. Rep. 8, 2681. https://doi.org/10.1038/s41598-018-21039-z (2018).
doi: 10.1038/s41598-018-21039-z
pubmed: 29422616
pmcid: 5805727
Bai, B. et al. Virus-like particles of SARS-like coronavirus formed by membrane proteins from different origins demonstrate stimulating activity in human dendritic cells. PLoS One. 3 (7), e2685. https://doi.org/10.1371/journal.pone.0002685 (2008). PMID: 18628832; PMCID: PMC2441860.
doi: 10.1371/journal.pone.0002685
pubmed: 18628832
pmcid: 2441860
Dai, S., Zhang, T., Zhang, Y., Wang, H. & Deng, F. Zika Virus Baculovirus-Expressed Virus-Like Particles Induce Neutralizing Antibodies in Mice. Virol Sin. ;33(3):213–226. doi: 10.1007/s12250-018-0030-5. Epub 2018 May 17. PMID: 29774519; PMCID: PMC6013542. (2018).
Bosio, C. M. et al. Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology. ;326(2):280-7. doi: (2004). https://doi.org/10.1016/j.virol.2004.05.025 . PMID: 15302213.
Walls, A. C. et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. bioRxiv [Preprint]. 2020 Aug 12:2020.08.11.247395. doi: 10.1101/2020.08.11.247395. Update in: Cell. 2020;: PMID: 32817941; PMCID: PMC7430571.
Davis, M. et al. A C57BL/6 Mouse model of SARS-CoV-2 infection recapitulates age- and sex-based differences in human COVID-19 disease and recovery. Res Sq [Preprint]. 2022 Nov 14:rs.3.rs-2194450. doi: (2022). https://doi.org/10.21203/rs.3.rs-2194450/v1 . Update in: Vaccines (Basel). ;11(1):47. doi: 10.3390/vaccines11010047. PMID: 36415465; PMCID: PMC9681052.
Darif, D. et al. The pro-inflammatory cytokines in COVID-19 pathogenesis: what goes wrong? Microb. Pathog. 153, 104799. https://doi.org/10.1016/j.micpath.2021.104799 (2021). Epub 2021 Feb 18. PMID: 33609650; PMCID: PMC7889464.
doi: 10.1016/j.micpath.2021.104799
pubmed: 33609650
pmcid: 7889464
Rabaan, A. A. et al. Role of inflammatory cytokines in COVID-19 patients: a review on Molecular mechanisms, Immune functions, Immunopathology and Immunomodulatory drugs to Counter Cytokine Storm. Vaccines (Basel). 9 (5), 436. https://doi.org/10.3390/vaccines9050436 (2021). PMID: 33946736; PMCID: PMC8145892.
doi: 10.3390/vaccines9050436
pubmed: 33946736
Zhang, Q. et al. Inflammation and antiviral Immune Response Associated with severe progression of COVID-19. Front. Immunol. 12, 631226. https://doi.org/10.3389/fimmu.2021.631226 (2021). PMID: 33679778; PMCID: PMC7930228.
doi: 10.3389/fimmu.2021.631226
pubmed: 33679778
pmcid: 7930228
Faraj, S. S., Jalal, P. J. & IL1β IL-6, and TNF-α cytokines cooperate to modulate a complicated medical condition among COVID-19 patients: case-control study. Ann. Med. Surg. (Lond). 85 (6), 2291–2297. https://doi.org/10.1097/MS9.0000000000000679 (2023). PMID: 37363608; PMCID: PMC10289607.